Episode
New Approaches: Marstacimab Therapy and HLH Biomarkers
- Podcast
- Blood Podcast
- Published
- May 28, 2026
- Duration seconds
- 1070
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/18f11dc5
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/new-approaches-marstacimab-therapy-and-hlh-biomarkers/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/new-approaches-marstacimab-therapy-and-hlh-biomarkers.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood . Dr. Mahlangu discusses study details and next steps from " Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial " which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind " CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis ", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.